$17.20
+0.48 (+2.87%)
Last updated: May 31, 2026 07:44
Fundamentals Overview
Tandem Diabetes Care, Inc. is in the middle of its 52-week range with low valuation, trending upward today.
Valuation low
Risk (Beta)
1.64 — higher vol
BullzEye Analysis
Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Sentiment improving (5 upgrades)
Pressures (Sell):
Analyst grade: D+ · 3M vs S&P 500: -43% · 3M vs Healthcare sector: -28.6% · Beta 1.64 (elevated)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: D+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 5, Equal Weight: 4, Hold: 6, Market Perform: 1, Neutral: 10, Outperform: 1, Overweight: 3.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-46.88; current price is $17.20. That’s a -372.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 8.89 |
| P/S (TTM) | 1.15 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 3.58 |
| Quick Ratio (TTM) | 3.07 |
| Cash Ratio (TTM) | 0.72 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -9.2% |
| Gross margin (TTM) | 54.93% |
| Operating margin (TTM) | -7.88% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for TNDM.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Citigroup | maintain | Neutral | Neutral | 2026-05-28 |
| B of A Securities | maintain | Neutral | Neutral | 2026-05-18 |
| Barclays | maintain | Overweight | Overweight | 2026-05-11 |
| Truist Securities | maintain | Buy | Buy | 2026-05-11 |
| TD Cowen | maintain | Buy | Buy | 2026-04-20 |
| Goldman Sachs | maintain | Neutral | Neutral | 2026-04-09 |
| Truist Securities | upgrade | Hold | Buy | 2026-03-19 |
| Piper Sandler | upgrade | Neutral | Overweight | 2026-03-17 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-03-02 |
| Truist Securities | maintain | Hold | Hold | 2026-02-23 |
| Lake Street | upgrade | Hold | Buy | 2026-02-23 |
| Piper Sandler | maintain | Neutral | Neutral | 2026-02-20 |
| Stifel | maintain | Hold | Hold | 2026-02-20 |
| UBS | maintain | Neutral | Neutral | 2026-02-20 |
| Mizuho | maintain | Neutral | Neutral | 2026-02-20 |
| B of A Securities | upgrade | Underperform | Neutral | 2026-02-20 |
| Stifel | maintain | Hold | Hold | 2026-02-04 |
| Bernstein | maintain | Market Perform | Market Perform | 2026-01-09 |
| Truist Securities | maintain | Hold | Hold | 2025-12-18 |
| Canaccord Genuity | maintain | Buy | Buy | 2025-12-17 |
| Mizuho | maintain | Neutral | Neutral | 2025-12-17 |
| Baird | upgrade | Neutral | Outperform | 2025-12-16 |
| Citigroup | maintain | Neutral | Neutral | 2025-12-11 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-12-02 |
| Barclays | maintain | Overweight | Overweight | 2025-11-10 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-11-10 |
| Truist Securities | maintain | Hold | Hold | 2025-11-10 |
| Wells Fargo | maintain | Equal Weight | Equal Weight | 2025-11-07 |
| Truist Securities | maintain | Hold | Hold | 2025-10-15 |
| Citigroup | maintain | Neutral | Neutral | 2025-10-07 |